SK Capital, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, has signed a definitive agreement to acquire Perrigo API, Perrigo Company plc’s (NYSE; TASE: PRGO) active pharmaceutical ingredients business.